Prostate cancer early detection practices among men with a family history of disease

Urology

Volumn 62, Issue 3, 2003, Pages 470-475

  Bock, Cathryn H ^b   Peyser, Patricia A ^b   Gruber, Stephen B ^b   Bonnell, Susan E ^b   Tedesco, Karen L ^b   Cooney, Kathleen A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER SUSCEPTIBILITY; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; FAMILIAL CANCER; FAMILY HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0041733431     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00382-0     Document Type: Article

References (26)

1. Smith R.A., von Eschenbach A.C., Wender R., et al. American Cancer Society guidelines for the early detection of cancer - update of early detection guidelines for prostate, colorectal, and endometrial cancers and update 2001 testing for early lung cancer detection . CA Cancer J Clin. 51:2001;38-75.
2. Carroll P., Coley C., McLeod D., et al. Prostate-specific antigen best practice policy - part I early detection and diagnosis of prostate cancer . Urology. 57:2001;217-224.
3. Potter S.R., Partin A. NCCN practice guidelines for early detection of prostate cancer. Oncology. 13:1999;99-115.
4. Screening for prostate cancer recommendation and rationale . Ann Intern Med. 137:2002;915-916.
5. Coley C.M., Barry M.J., Fleming C., et al. Early detection of prostate cancer, part II estimating the risks, benefits, and costs . Ann Intern Med. 126:1997;468-479.
6. Ferrini R., Woolf S.H. Screening for prostate cancer in American men American College of Preventive Medicine Practice Policy Statement . Am J Prev Med. 15:1988;81-84.
7. McDavid K., Melnik T.A., Derderian H. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997. Prev Med. 31:2000;195-202.
8. Michigan Public Health Institute: Screening for Prostate and Colorectal Cancer: Findings from Surveys of Adults and Primary Care Physicians in Michigan - Volume I: Prostate Cancer. Ann Arbor, Michigan Public Health Institute, 1997.
9. Close D.R., Kristal A.R., Li S., et al. Associations of demographic and health-related characteristics with prostate cancer screening in Washington state. Cancer Epidemiol Biomarkers Prev. 7:1998;627-630.
10. Lemon S., Zapka J., Puleo E., et al. Colorectal cancer screening participation comparisons with mammography and prostate-specific antigen screening . Am J Pub Health. 91:2001;1264-1272.
11. Bratt O., Damber J.-E., Emanuelsson M., et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer. 36:2000;235-241.
12. Miller S.M., Diefenbach M.A., Kruus L.K., et al. Psychological and screening profiles of first-degree relatives of prostate cancer patients. J Behav Med. 24:2001;247-258.
13. Cooney K.A., McCarthy J.D., Lange E., et al. Prostate cancer susceptibility locus on chromosome 1q a confirmatory study . J Natl Cancer Inst. 89:1997;955-959.
14. Lange E.M., Chen H., Brierley K., et al. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res. 5:1999;4013-4020.
15. Bock C.H., Cunningham J.M., McDonnell S.K., et al. Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer. Am J Hum Genet. 68:2001;795-801.
16. Cooney K.A., Strawderman M.S., Wojno K.J., et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology. 57:2001;91-96.
17. Stanford JL, Stephenson RA, Coyle LM, et al: Prostate Cancer Trends 1973-1995, NIH Publication No. 99-4543. Bethesda, National Institutes of Health, 1999.
18. Liang K.Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 73:1986;13-22.
19. Harris R, Lohr KN, Beck R, et al: Screening for prostate cancer: systematic evidence review No. 16. Rockville, Maryland, Agency for Healthcare Research and Quality, http://www.ahrq.gov/clinic/serfiles.htm, 2002. Accessed February 26, 2003.
20. Carter H.B. A PSA threshold of 4.0 ng/mL for early de-tection of prostate cancer the only rational approach for men 50 years old and older . Urology. 55:2000;796-799.
21. Catalona W.J., Ramos C.G., Carvalhal G.F., et al. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 55:2000;791-795.
22. Babaian R.J., Johnston D.A., Naccarato W., et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml relation to biopsy strategy . J Urol. 165:2001;757-760.
23. Gordon N.P., Hiatt R.A., Lampert D.I. Concordance of self-reported data and medical record audit for six cancer screening procedures. J Natl Cancer Inst. 85:1993;566-570.
24. Jordan T.R., Price J.H., King K.A., et al. The validity of male patients' self-reports regarding prostate cancer screening. Prev Med. 28:1999;297-303.
25. Zhu K., McKnight B., Stergachis A., et al. Comparison of self-report data and medical records data results from a case-control study on prostate cancer . Int J Epidemiol. 28:1999;409-417.
26. Ries LAG, Eisner MP, Kosary CL, et al (Eds): SEER cancer statistics review, 1973-1999. Bethesda, National Cancer Institute, http://seer.cancer.gov/csr/1973_1999/, 2002. Accessed April 15, 2002.